(No ratings)
Dr. Eva Catharina Guinan, MD is a pediatric oncologist in BOSTON, MA specializing in pediatric hematology/oncology. She graduated from Harvard Medical School. Dr. Eva Catharina Guinan, MD is affiliated with Dana-Farber Cancer Institute.
Dr. Eva Catharina Guinan, MD graduated from Harvard Medical School. She completed residency at Children's Hospital Boston. She is certified by the Board Certification:Pediatrics and has a state license in Massachusetts.
Medical School: Harvard Medical School
Residency: Children's Hospital Boston
Board Certification: Board Certification:Pediatrics (1986)
Licensed In: Massachusetts
Dr. Eva Catharina Guinan, MD does not have any reviews yet, be the first to leave a review of Dr. Eva Catharina Guinan, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Eva Catharina Guinan, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| AstraZeneca Pharmaceuticals LP |
$18,600
SAPHNELO $12,000 |
$6,600 |
|
|---|---|---|---|
| Sandoz Inc. |
$7,777
$7,777 |
||
| Novartis Pharmaceuticals Corporation |
$7,701
KYMRIAH $7,701 |
||
| E.R. Squibb & Sons, L.L.C. |
$5,771
$5,771 |
||
| Ortho Dermatologics, a division of Bausch Health US, LLC |
$1,938
ELIDEL $1,938 |
||
| Other |
$3,573
ELIDEL $3,000 |
XOLAIR $544 |
NON-PRODUCT $29 |
| Consulting Fee | $43,073 |
|---|---|
| Travel and Lodging | $1,900 |
| Food and Beverage | $357 |
| Education | $29 |
Dr. Eva Catharina Guinan, MD has received 3 research payments totaling $98,313.
Dr Guinan received her MD from Harvard Medical School in 1980, followed by a pediatric residency at Children's Hospital and a pediatric hematology-oncology fellowship at Children's Hospital and DFCI. She was appointed associate director of the Bone Marrow Transplant Service in 1990 and directed the program from 1997 through 2005. She assumed a new position in 2005 as the Associate Director of the Center for Clinical and Translational Research. Her own translational research program focuses on the costimulatory blockade as a mechanism of overcoming problems related to allogenicity in transplantation and the amelioration of regimen-related toxicity.